Current role for combination therapy in male luts;Papel actual de la terapia combinada en los síntomas del tracto urinario inferior (stui) masculino

Archivos Espanoles de Urologia

Volumn 63, Issue 5, 2010, Pages 323-332

  Chung, Doreen E ^b   Kaplan, Steven A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

Adrenergic alpha antagonists; Benign; Cholinergic antagonists; Overactive; Prostatic hyperplasia; Urinary bladder

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTENONE 5ALPHA REDUCTASE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; DRUG ANTAGONISM; DRUG COMBINATION; HUMAN; MALE; PROSTATISM;

ADRENERGIC ALPHA-ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; DRUG THERAPY, COMBINATION; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PROSTATISM;

EID: 77957854567     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Irwin D, Milsom I, Hunskaar S, et al. Populationbased survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; (50):1306-14. (Pubitemid 44692945)
2. Kirby R, Lepor H. Evaluation and non-surgical management of benign prostatic hypeplasia. In: Wein A, Kavoussi L, Novick A, Partin A, Peters C, editors. Campbell-Walsh Urology, 9th ed. Philadelphia: Saunders Elsevier; 2007.
3. Guideline on the Management of Benign Prostatic Hyperplasia (HBP). Journal [serial on the Internet]. 2003 Date.
4. de La Rosette J, Alivizatos G, Madersbacher M, Rioja Sanz C, Nordling J. Guidelines on benign Prostatic Hyperplasia. Journal [serial on the Internet]. 2004 Date.
5. Chapple C. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU International. 2004;94:738-44. (Pubitemid 39243946)
6. McVary K, Roehrborn C, Kaminetsky J, al e. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1404-7. (Pubitemid 46435965)
7. Abrams P, Cardozo L, Fall M, al. e. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology. 2003;61:37-49. (Pubitemid 36151708)
8. Blake-James B, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and metaanalysis. BJU International. 2007;99(1):85-96. (Pubitemid 44915626)
9. Chapple C, Roehrborn C. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651-9. (Pubitemid 43374725)
10. McGuire E. Neuromuscular dysfunction of the lower urinary tract In: Walsh P, Gittes R, Perlmutter A, Stamey T, editors. Campbell's Urology. Philadelphia: W. B. Saunders; 1986. (Pubitemid 16042432)
11. Kaplan S, Roehrborn C, Rovner E, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319-28. (Pubitemid 44749359)
12. Kaplan S, Walmsley K, Te A. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2008;179(Suppl 5): S82-5. (Pubitemid 351483918)
13. Abrams P, Kaplan S, De Koning Gans H, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3):999-1004 (Pubitemid 43200054)
14. Lee J, Kim H, Lee S, Koh J, Suh H, Chancellor M. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU International. 2004;94(6):817-20. (Pubitemid 39472476)
15. McConnell J, Roehrborn C, Bautista O, Andriole JL, et al. Group tMToPSMR. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. NEJM. 2003;349:2387-98. (Pubitemid 37542987)
16. MacDiarmid S, Peters K, Chen A, Armstrong R, Orman C, Aquilina J, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized doubleblind placebo-controlled study. Mayo Clin Proc. 2008;83(9):1002-10.
17. Elhilali M, Ramsey E, Barkin J, Casey R, Boake R, Beland G, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology. 1996;47:335-42. (Pubitemid 26089511)
18. Roehrborn C. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 2001;58:953-9. (Pubitemid 32728056)
19. Roehrborn C, Siegel R. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebocontrolled studies. Urology. 1996;48:406-15. (Pubitemid 26317481)
20. Debruyne F. Alpha blockers: are all created equal?. Urology. 2000;56(5 suppl 1):20-2.
21. Roehrborn C, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92:257-61. (Pubitemid 36966589)
22. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998;51:892-900. (Pubitemid 28240845)
23. McConnell J. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate. 1990;3(Suppl): 49-59. (Pubitemid 20127951)
24. Kaplan S, McConnell J. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 mL or greater. J Urol. 2006;175(1):217-20. (Pubitemid 43067393)
25. Boyle P, Gould A, Roehrborn C. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996;48:398-405. (Pubitemid 26317480)
26. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 1993;22:291-9.
27. Gormley G, Stoner E, Bruskewitz R, Imperato-McGinley J, Walsh P, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185-91.
28. Marberger MJ, PROWESS Study Group. Longterm effects of finasteride in patients with benign prostatic hyper-plasia: a double-blind, placebo-controlled, multi-center study. Urol, 1998;51:677-86.
29. McConnell J, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe H, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557-63. (Pubitemid 28114643)
30. Roehrborn C, Boyle P, Nickel J, Hoefner K, Andriole G, et al. ARIA3002, and ARIA3003 Study In-vestigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434-41.
31. Hyman M, Groutz A, Blaivas J. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001;166:550-2. (Pubitemid 32652245)
32. Laniado M, Ockrim J, Marronaro A, Tubaro A, Carter S. Serum prostate specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU International. 2004;94:1283-6. (Pubitemid 40052094)
33. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology. 2001;57:414-21. (Pubitemid 32192963)
34. Cardozo L, Lisec M, Millard R, van Vierssen Trip, et al. Randomized double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;1:1919-1924. (Pubitemid 39363090)
35. Kirby R, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. for the Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61:119-26.
36. Kaplan S, McConnell J, Roehrborn C, Meehan A, Lee M, Noble W, et al. Combination Therapy With Doxazosin and Finasteride for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptoms and a Baseline Total Prostate Volume of 25 mL or Greater J Urol. 2006;175(1):217-20. (Pubitemid 43067393)
37. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip O, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003;44:461-6. (Pubitemid 37185673)
38. Roehrborn C, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616-21.
39. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled trial. J Urol. 2003;169:2253-6. (Pubitemid 36576764)
40. Lee K, Choo M, Kim D, Kim J, Min K, Lee J, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174:1334-8. (Pubitemid 41318723)
41. Kaplan S, Roehrborn C, Rovner E, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2007;296(19):2319-28. (Pubitemid 44749359)
42. Kaplan S, Roehrborn C, Chancellor M, Carlsson M, Bavendam T, Guan Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the international prostate symptom score. BJU International. 2008;102(9):1133-9.
43. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol, 2009;56(3):534-41
44. Rovner E, Kreder K, Sussman D, Kaplan S, Carlsson M, Bavendam T, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008;180(3):1034-41.
45. Roehrborn C, Kaplan S, Kraus S, Wang J, Bavendam T, Guan Z. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS including OAB. Urology. 2008;72(5):1061-7.
46. Roehrborn C, Kaplan S, Jones J, Wang J, Bavendam T, Guan Z. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effect of prostate size. Eur Urol, 2009;55(2):472-479.
47. Chung D, Te A, Staskin D, Kaplan S. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates ≥ 30grams. Urol, 2010;75:1144-8.